Abstract
Chronic kidney disease as identified by a reduced estimated glomerular filtration rate and/or evidence of microalbuminuria is an established cardiovascular risk state for the development of atherosclerosis, myocardial disease, valvular disease, and heart failure. Screening for atherosclerosis risk factors and optimal management is indicated in all patients. Accelerated vascular calcification is the most prominent feature of atherosclerosis in patients with chronic kidney disease. Recognition that heart failure is the most common manifestation of cardiovascular disease is important since the principles of blood pressure control and use of particular antihypertensive agents can reduce the incidence of symptomatic heart failure. The cardiomyopathy of chronic kidney disease is manifested by left ventricular hypertrophy, evidence of diastolic dysfunction with or without superimposed systolic dysfunction. Increased blood levels of B-type natriuretic peptide, N-terminal pro B-type natriuretic peptide, galectin-3, and ST2 all are consistent and supportive of a diagnosis of heart failure. Conversely, low or normal levels of these proteins have a very high negative predictive value in excluding the presence of heart failure. Aortic valve sclerosis/stenosis and mitral annular calcification, both readily identified by echocardiography, are the most common forms of valvular disease in patients with chronic kidney disease. All forms of arrhythmias are more common in patients with kidney disease compared to the general population. Because sudden death can be the first manifestation of arrhythmias, particularly in patients with end-stage renal disease, heightened awareness, low thresholds for monitoring, and implantation of cardio-defibrillators should be considered in appropriate patients.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Chen SC, Su HM, Tsai YC, Huang JC, Chang JM, Hwang SJ, et al. Framingham risk score with cardiovascular events in chronic kidney disease. PLoS One. 2013;8(3):e60008.
McCullough PA. Cardiovascular disease in chronic kidney disease from a cardiologist’s perspective. Curr Opin Nephrol Hypertens. 2004;13(6):591–600.
Keeley EC, McCullough PA. Coronary revascularization in patients with coronary artery disease and chronic kidney disease. Adv Chronic Kidney Dis. 2004;11(3):254–60.
McCullough PA, Agrawal V, Danielewicz E, Abela GS. Accelerated atherosclerotic calcification and Mönckeberg’s sclerosis: a continuum of advanced vascular pathology in chronic kidney disease. Clin J Am Soc Nephrol. 2008;3(6):1585–98.
McCullough PA, Agarwal M, Agrawal V. Review article: risks of coronary artery calcification in chronic kidney disease: do the same rules apply? Nephrology (Carlton). 2009;14(4):428–36.
KDIGO clinical practice guidelines for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int. 2009;76(113):S1–S130.
McCullough PA, Jurkovitz CT, Pergola PE, McGill JB, Brown WW, Collins AJ, KEEP Investigators, et al. Independent components of chronic kidney disease as a cardiovascular risk state: results from the kidney early evaluation program (KEEP). Arch Intern Med. 2007;167(11):1122–9.
McCullough PA, Li S, Jurkovitz CT, Stevens L, Collins AJ, Chen SC, KEEP Investigators, et al. Chronic kidney disease, prevalence of premature cardiovascular disease, and relationship to short-term mortality. Am Heart J. 2008;156(2):277–83.
Ronco C, McCullough PA, Anker SD, Anand I, Aspromonte N, Bagshaw SM, et al. Cardiorenal syndromes: an executive summary from the consensus conference of the acute dialysis quality initiative (ADQI). Contrib Nephrol. 2010;165:54–67.
National Kidney Foundation. K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients. Am J Kidney Dis. 2005;45:S1–153.
Vanhecke TE, Franklin BA, Soman P, Lahiri A, Mieres JH, Sias T, et al. Influence of myocardial ischemia on outcomes in patients with systolic versus non-systolic heart failure. Am J Cardiovasc Dis. 2011;1(2):167–75.
Grunukula SR, Spodick DH. Pericardial disease in renal patients. Semin Nephrol. 2001;21:52.
McCullough PA, Olobatoke A, Vanhecke TE. Galectin-3: a novel blood test for the evaluation and management of patients with heart failure. Rev Cardiovasc Med. 2011;12(4):200–10.
Wase A, Basit A, Nazir R, Jamal A, Shah S, Khan T, et al. Impact of chronic kidney disease upon survival among implantable cardioverter-defibrillator recipients. J Interv Card Electrophysiol. 2004;11(3):199–204.
Best PJ, Reddan DN, Berger PB, Szczech LA, McCullough PA, Califf RM. Cardiovascular disease and chronic kidney disease: insights and an update. Am Heart J. 2004;148(2):230–42.
Fihn SD, Gardin JM, Abrams J, Berra K, Blankenship JC, Dallas AP, Douglas PS, Foody JM, Gerber TC, Hinderliter AL, King 3rd SB, Kligfield PD, Krumholz HM, Kwong RY, Lim MJ, Linderbaum JA, Mack MJ, Munger MA, Prager RL, Sabik JF, Shaw LJ, Sikkema JD, Smith Jr CR, Smith Jr SC, Spertus JA, Williams SV, American College of Cardiology Foundation. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: executive summary. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation. 2012;126:3097–137.
Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, Chambers CE, Ellis SG, Guyton RA, Hollenberg SM, Khot UN, Lange RA, Mauri L, Mehran R, Moussa ID, Mukherjee D, Nallamothu BK, Ting HH. 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention: executive summary. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation. 2011;124:2574–609.
National Kidney Foundation. K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients. Am J Kidney Dis. 2005;45 Suppl 3:S1–154.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
McCullough, P.A., Nasser, M. (2014). Screening and Diagnosing Cardiovascular Disease in Chronic Kidney Disease. In: Arici, M. (eds) Management of Chronic Kidney Disease. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-54637-2_12
Download citation
DOI: https://doi.org/10.1007/978-3-642-54637-2_12
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-54636-5
Online ISBN: 978-3-642-54637-2
eBook Packages: MedicineMedicine (R0)